CA
VRTX icon

Claro Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Claro Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$718K Sell
1,445
-161
-10% -$71.4K 0.08% 208
2026
Q1 		$717K Sell
1,606
-99
-6% -$46.2K 0.09% 186
2025
Q4 		$773K Sell
1,705
-13
-0.8% -$5.6K 0.11% 171
2025
Q3 		$673K Sell
1,718
-828
-33% -$346K 0.1% 179
2025
Q2 		$1.13M Sell
2,546
-392
-13% -$181K 0.19% 104
2025
Q1 		$1.42M Sell
2,938
-137
-4% -$63.8K 0.19% 97
2024
Q4 		$1.24M Buy
3,075
+650
+27% +$301K 0.17% 110
2024
Q3 		$1.13M Buy
2,425
+471
+24% +$226K 0.15% 135
2024
Q2 		$916K Buy
1,954
+591
+43% +$257K 0.14% 142
2024
Q1 		$570K Buy
1,363
+98
+8% +$41.4K 0.1% 215
2023
Q4 		$515K Buy
1,265
+56
+5% +$20.7K 0.11% 210
2023
Q3 		$420K Buy
1,209
+143
+13% +$50K 0.11% 221
2023
Q2 		$375K Buy
+1,066
New +$359K 0.09% 235
2019
Q1 		– Sell
-343
Closed -$66K – 920
2018
Q4 		$66K Buy
+343
New +$59.4K 0.05% 296

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Claro Advisors's VRTX Position: Q2 2026 in Review

Claro Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 10% in Q2 2026, selling an estimated $71.4K and leaving 1,445 shares worth $718K. The position accounts for 0.08% of the portfolio, ranked #208.

Claro Advisors first reported a position in VRTX in Q4 2018 and has held it in 14 quarters since. The position peaked at $1.42M in Q1 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Claro Advisors held 1,445 shares of Vertex Pharmaceuticals worth $718K as of Q2 2026.
  • Claro Advisors sold 161 Vertex Pharmaceuticals shares in Q2 2026, an estimated $71.4K.
  • Vertex Pharmaceuticals made up 0.08% of Claro Advisors's portfolio in Q2 2026, its #208 holding.
  • Claro Advisors first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 14 quarters since.
  • Claro Advisors's Vertex Pharmaceuticals position peaked at $1.42M in Q1 2025.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Claro Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.